Zynerba pharmaceuticals.
Zynerba Pharmaceuticals last issued its earnings data on August 14th, 2023. The reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01. Zynerba Pharmaceuticals has generated ($0.80) earnings per share over the last year ( ($0.80) diluted earnings per share).
According to the issued ratings of 4 analysts in the last year, the consensus rating for Zynerba Pharmaceuticals stock is Hold based on the current 3 hold ratings and 1 buy rating for ZYNE. The average twelve-month price prediction for Zynerba Pharmaceuticals is $1.11 with a high price target of $1.11 and a low price target of $1.11.ZYN002 (Zynerba Pharmaceuticals, Devon, PA, USA), a pharmaceutically-produced CBD, is being promoted as a therapeutic option for various neuropsychiatric disorders. The company highlights ZYN002 as being the first and only permeance-enhanced synthetic CBD gel in use for disorders such as fragile X syndrome, adult refractory focal …© 2023 Zynerba Pharmaceuticals, Inc. All rights reserved. 80 W. Lancaster Avenue, Suite 300 Devon, PA 19333 484.581.7505Number of Employees. Zynerba Pharmaceuticals, Inc. number of employees from 2015 to 2023. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Zynerba Pharmaceuticals, Inc. Annual Number of Employees. 2022.Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 deletion …
Zynerba Pharmaceuticals | 4,540 followers on LinkedIn. Advancing Sciences | Improving Connections | Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare ...
Zynerba is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives …Legal Name Zynerba Pharmaceuticals, Inc. Stock Symbol NASDAQ:ZYNE. Company Type For Profit. Phone Number +1 484 581 7505. Zynerba Pharmaceuticals is dedicated to the development of innovative transdermal cannabinoid treatments for patients with high unmet medical needs using modern drug delivery technology and appropriate regulatory …
Harmony Biosciences Holdings has agreed to acquire Zynerba Pharmaceuticals for up to $200 million in a deal involving two suburban Philadelphia life sciences companies. Zynerba's stock pice soared ...Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 …Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, 22q11.2 deletion …Oct 17, 2022 · Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of ...
Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome and 22q11.2 deletion syndrome.
Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of ...
The pain management therapeutics market is likely to grow at a CAGR of 4.8% by 2026. Through the primary research, it was established that the pain management therapeutics market was valued at ...Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has revised its timeline for releasing topline results from its multiple-centre Phase 3 RECONNECT trial, which sees Zygel administered to children and adolescents aged from three to 17 to treat symptoms of Fragile X syndrome (FXS). The pharma group said factors including the so-called …DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan ...Redotex is a drug that is sometimes prescribed or recommended as a weight loss aid. It is produced in Mexico by the Medix pharmaceutical company and is banned in a number of countries, including the United States.At Zynerba Pharmaceuticals, our team is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for patients affected by rare neuropsychiatric conditions. Often, these conditions have few, if any, treatment options and can leave patients and their families feeling helpless and alone.
Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome and 22q11.2 deletion syndrome.Zynerba is a leader in pharmaceutically produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders.About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders.Zygel is the first and only pharmaceutically-manufactured cannabidiol, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the …DEVON, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal …May 16, 2022 · Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, and 22q11 ...
An Open-label Trial Assessing Short- and Long-term Tolerability and Efficacy of ZYN002 (Cannabidiol) Administered as a Transdermal Gel to Children and Adolescents with 22q11.2 Deletion Syndrome (INSPIRE). The Society for the Study of Behavioural Phenotypes (SSBP) 25 th International Research Symposium, September 15, 2023. Presentation.
Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, 22q11.2 deletion …Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, 22q11.2 deletion syndrome and autism …$1.30. As on 13-Oct-2023 09:30 EST. $0.00 • 0.00% · Prev Close info. $1.30 · Day's Open info. $1.30 · Today's High info. $1.30 · Today's Low info. $1.30.Kisner served on the board of directors of Tekmira Pharmaceuticals from 2010 until March 2015 and Lpath Inc. from July 2012 until December 2016, and he currently serves on the boards of directors of Dynavax Technologies Corporation chairing the Nominating and Governance Committee, Oncternal Therapeutics (Audit and Compensation Committee) …Zynerba Pharmaceuticals, Inc. cash on hand from 2015 to 2023. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.© 2023 Zynerba Pharmaceuticals, Inc. All rights reserved. 80 W. Lancaster Avenue, Suite 300 Devon, PA 19333 484.581.7505Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, 22q11.2 deletion syndrome and autism …Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of ...Harmony Biosciences Holdings said Wednesday it has extended the expiration of its tender offer to acquire all of the outstanding shares of Zynerba Pharmaceuticals to 5 p.m. on Oct. 10. The ...$1.30. As on 13-Oct-2023 09:30 EST. $0.00 • 0.00% · Prev Close info. $1.30 · Day's Open info. $1.30 · Today's High info. $1.30 · Today's Low info. $1.30.
Aug 14, 2023 · About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically produced, synthetic transdermal cannabidiol therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome ...
Get the latest Zynerba Pharmaceuticals, Inc. (ZYNE) stock news and headlines to help you in your trading and investing decisions.
Harmony’s tender offer to acquire all outstanding shares of Zynerba for a purchase price of $1.1059 per share in cash, or $60 million in the aggregate, plus one non-tradeable contingent value right (CVR) per share, representing the right to receive potential additional payments of up to $140 million or approximately $2.5444 in additional cash ...Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of ...ZYNERBA PHARMACEUTICALS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Zynerba Pharmaceuticals Inc | A14XCV | ZYNE | US98986X1090.Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for ...Nov 25, 2023 · Earnings for Zynerba Pharmaceuticals are expected to grow in the coming year, from ($0.84) to ($0.49) per share. Price to Earnings Ratio vs. the Market. The P/E ratio of Zynerba Pharmaceuticals is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Zynerba Pharmaceuticals has such a small amount of debt that we'll set it aside, and focus on the US$59m in cash it held at December 2020. Importantly, its cash burn was US$42m over the trailing ...The pain management therapeutics market is likely to grow at a CAGR of 4.8% by 2026. Through the primary research, it was established that the pain management therapeutics market was valued at ...Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, and 22q11 ...Item 1.01. Entry into a Material Definitive Agreement. Merger Agreement On August 14, 2023, Zynerba Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Zynerba”), Harmony Biosciences Holdings, Inc., a Delaware corporation (“Parent” or “Harmony”), and Xylophone Acquisition Corp., a Delaware corporation and a wholly …
Jun 22, 2022 · Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the ... Albert P. Parker. Biopharma C-Suite Executive. Zynerba Pharmaceuticals University of Pennsylvania Law School. Greater Philadelphia. 2K followers ...Total Liabilities. Share Holder Equity. Zynerba Pharmaceuticals, Inc. long-term investments from 2015 to 2023. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year. Zynerba Pharmaceuticals, Inc. Annual Long-Term Investments. (Millions of US $) …Instagram:https://instagram. stock option strategiessaratoga datewhat is webull paper tradingchewy stocks Wall Street is set for a cautious start to the final week of November amid one of the strongest S&P 500 rallies in the last 100 years.Zynerba Pharmaceuticals; Strategic Partners. Our Strategic Partners lead the way in supporting research, finding new therapies, and breaking down social barriers as a demonstration of their company’s commitment to ending the fight against seizures. The following Strategic Partners have committed $5,000–$24,999 toward joining the quest to ... what is the best free portfolio trackerfisher price sensory bright light station Zynerba Pharmaceuticals, Inc. cash on hand from 2015 to 2023. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! imperium stock symbol At Zynerba Pharmaceuticals, our team is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for patients affected by rare neuropsychiatric conditions. Often, these conditions have few, if any, treatment options and can leave patients and their families feeling helpless and alone. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum …